Fibroblast growth factor 21 (FGF21) is a distinctive member of the FGF family with potent beneficial effects on lipid, body weight, and glucose metabolism and has attracted considerable interest as a potential therapeutic for treating diabetes and obesity. As an alternative to native FGF21, we have developed a monoclonal antibody, mimAb1, that binds to βKlotho with high affinity and specifically activates signaling from the βKlotho/FGFR1c (FGF receptor 1c) receptor complex. In obese cynomolgus monkeys, injection of mimAb1 led to FGF21-like metabolic effects, including decreases in body weight, plasma insulin, triglycerides, and glucose during tolerance testing. Mice with adipose-selective FGFR1 knockout were refractory to FGF21-induced improvements in glucose metabolism and body weight. These results in obese monkeys (with mimAb1) and in FGFR1 knockout mice (with FGF21) demonstrated the essential role of FGFR1c in FGF21 function and suggest fat as a critical target tissue for the cytokine and antibody. Because mimAb1 depends on βKlotho to activate FGFR1c, it is not expected to induce side effects caused by activating FGFR1c alone. The unexpected finding of an antibody that can activate FGF21-like signaling through cell surface receptors provided preclinical validation for an innovative therapeutic approach to diabetes and obesity.

Immunostimulatory oligodeoxynucleotides (ODN) containing cytosine-guanine (CpG) motifs are powerful stimulators of innate as well as adaptive immune responses, exerting their activity through triggering of the Toll-like receptor 9. We have previously shown that encapsulation in liposomal nanoparticles (LN) enhances the immunostimulatory activity of CpG ODN (LN-CpG ODN) (Mui et al. in J Pharmacol Exp Ther 298:1185, 2001). In this work we investigate the effect of encapsulation on the immunopotency of subcutaneously (s.c.) administered CpG ODN with regard to activation of innate immune cells as well as its ability to act as a vaccine adjuvant with tumor-associated antigens (TAAs) to induce antigen (Ag)-specific, adaptive responses and anti-tumor activity in murine models. It is shown that encapsulation specifically targets CpG ODN for uptake by immune cells. This may provide the basis, at least in part, for the significantly enhanced immunostimulatory activity of LN-CpG ODN, inducing potent innate (as judged by immune cell activation and plasma cytokine/chemokine levels) and adaptive, Ag-specific (as judged by MHC tetramer positive T lymphocytes, IFN-gamma secretion and cytotoxicity) immune responses. Finally, in efficacy studies, it is shown that liposomal encapsulation enhances the ability of CpG ODN to adjuvanate adaptive immune responses against co-administered TAAs after s.c. immunization, inducing effective anti-tumor activity against both model and syngeneic tumor Ags in murine tumor models of thymoma and melanoma.

Previous work (Wheeler et al, Gene Therapy 1999; 6: 271-be generated. The SPLP produced could be isolated from 281) has shown that plasmid DNA can be entrapped in empty vesicles by sucrose density gradient centrifugation, 'stabilized plasmid-lipid particles' (SPLP) containing the and exhibited a narrow size distribution (62 ± 8 nm, as fusogenic lipid dioleoylphosphatidylethanolamine (DOPE), determined by freeze-fracture electron microscopy) and a low levels (5-10 mol%) of cationic lipid, and stabilized by high plasmid-to-lipid ratio of 65 g/ mol (corresponding to a polyethyleneglycol (PEG) coating. The PEG moieties are one plasmid per particle) regardless of the DODAC conattached to a ceramide anchor containing an arachidoyl tent. It was found that isolated SPLP containing 20-acyl group (PEG-CerC 20 ). These SPLP exhibit low trans-24 mol% DODAC resulted in optimum transfection of COSfection potencies in vitro, due in part to the long residence 7 and HepG2 cells in vitro, with luciferase expression levels time of the PEG-CerC 20 on the SPLP surface. In this work comparable to those achieved for plasmid DNA-cationic we employed SPLP stabilized by PEG attached to ceralipid complexes. In vivo studies employing an intraperimide containing an octanoyl acyl group (PEG-CerC 8 ), toneal B16 tumor model and intraperitoneal administration which is able to quickly exchange out of the SPLP, to of SPLP also demonstrated maximum luciferase develop systems that give rise to optimized in vitro and in expression for DODAC contents of 20-24 mol% and sigvivo (regional) transfection. A particular objective was to nificantly improved gene expression in tumor tissue as achieve cationic lipid contents that give rise to maximum compared with complexes. We conclude that SPLP stabiltransfection levels. It is shown that by performing the dialyized by PEG-CerC 8 and containing 20-24 mol% cationic sis procedure in the presence of increasing concentrations lipid are attractive alternatives to plasmid DNA-cationic of citrate, SPLP containing up to 30 mol% of the cationic lipid complexes for regional gene therapy applications. lipid dioleoydimethylammonium chloride (DODAC) could

No abstract

Background: Co-crystal structure of Fc-Fc␥RIII complex revealed that Fc binds to Fc␥RIII asymmetrically. Results: We identified a panel of novel Fc heterodimers with enhanced ADCC activity. Conclusion: Asymmetrical Fc engineering is an efficient approach for enhancing ADCC activity and stability of engineered antibodies. Significance: The discovery could be applied in therapeutic antibodies for the treatment of cancers and infectious diseases.